STEM has entered into an agreement to sell 7M shares of its common stock to Seaside 88, LP (“Seaside”), a private investment partnership, at a price of $0.865 per share, which represents a 12.6% discount to the closing price per share of 6/29/10. Read more…
Newly published independent research demonstrates that its GS2-M™ cell culture media formulation enhances the pluripotency of human embryonic stem (ES) and induced pluripotent stem (iPS) cells. Read more…
Revenues were $4.764 M. The net loss for Q3/10 was $1.365 M or $0.02 per share. For Q3/10, total revenues of $4.8 M (versus $6 M million in Q2/10). For Q3/10, KOOL reported total revenues of $4.8 M versus $6 M in Q2/10; recording disposable revenues of $3 M in Q3/10 versus $3.5 M in Q2/10. Read more…
STEM’s Q1/10, revenue was $230 K. The net loss was $6.124 M, or $(0.05) per share.
The increase in revenue ( 307%) was $230 K compared to $57,000 for Q1/09. The growth in revenue in 2010 was primarily due to the consolidation of the Stem Cell Sciences Plc (SCS) operations, which added product sales revenue from SCS portfolio of specialty cell culture products, as well as increased licensing and grant revenue include the operations of since 4/1/09. Read more…
StemCells (STEM) is seeking permission from the FDA to start a 2nd clinical trial of its proprietary HuCNS-SC human neural stem cells in neuronal ceroid lipofuscinosis (NCL), which is also often referred to as Batten disease.
Reported a smaller FY09 net loss of $27.02 M or $0.25 per share, an increase in revenues but, increased operational losses; versus a net loss of $29.08 M, or $0.35 per share for 2008.
STEM announced its proprietary HuCNS-SC® human neural stem cells have been used to treat the first patient enrolled in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD), a myelination disorder that afflicts male children. Read more…
StemCells Inc, a clinical-stage biotechnology company focuses on commercialization of products derived from stem cell technologies. STEM is targeting diseases of the central nervous system and liver. StemCells also markets specialty cell culture media products under the brand SC Proven ® and is developing its cell-based technologies for use in drug screening and drug development. (www.stemcellsinc.com) Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.